
This study evaluated the efficacy and safety of switching to insulin glargine 300 U/mL (Gla-300) in individuals with uncontrolled type 2 diabetes (T2D) previously treated with basal insulin. The results show a significant reduction in HbA1c, improved glycemic control, and a relatively low risk of hypoglycemia.
Like
Save
Share